Abstract
Interleukin-2-inducible T cell kinase (ITK) is a non-receptor tyrosine kinase expressed in T cells, NKT cells and mast cells which plays a crucial role in regulating the T cell receptor (TCR), CD28, CD2, chemokine receptor CXCR4, and FcηR-mediated signaling pathways. In T cells, ITK is an important mediator for actin reorganization, activation of PLCγ, mobilization of calcium, and activation of the NFAT transcription factor. ITK plays an important role in the secretion of IL-2, but more critically, also has a pivotal role in the secretion of Th2 cytokines, IL-4, IL-5 and IL-13. As such, ITK has been shown to regulate the development of effective Th2 response during allergic asthma as well as infections by parasitic worms. This ability of ITK to regulate Th2 responses, along with its pattern of expression, has led to the proposal that it would represent an excellent target for Th2-mediated inflammation. We discuss here the possibilities and pitfalls of targeting ITK for inflammatory disorders.
Current Topics in Medicinal Chemistry
Title: ITK Inhibitors in Inflammation and Immune-Mediated Disorders
Volume: 9 Issue: 8
Author(s): Nisebita Sahu and Avery August
Affiliation:
Abstract: Interleukin-2-inducible T cell kinase (ITK) is a non-receptor tyrosine kinase expressed in T cells, NKT cells and mast cells which plays a crucial role in regulating the T cell receptor (TCR), CD28, CD2, chemokine receptor CXCR4, and FcηR-mediated signaling pathways. In T cells, ITK is an important mediator for actin reorganization, activation of PLCγ, mobilization of calcium, and activation of the NFAT transcription factor. ITK plays an important role in the secretion of IL-2, but more critically, also has a pivotal role in the secretion of Th2 cytokines, IL-4, IL-5 and IL-13. As such, ITK has been shown to regulate the development of effective Th2 response during allergic asthma as well as infections by parasitic worms. This ability of ITK to regulate Th2 responses, along with its pattern of expression, has led to the proposal that it would represent an excellent target for Th2-mediated inflammation. We discuss here the possibilities and pitfalls of targeting ITK for inflammatory disorders.
Export Options
About this article
Cite this article as:
Sahu Nisebita and August Avery, ITK Inhibitors in Inflammation and Immune-Mediated Disorders, Current Topics in Medicinal Chemistry 2009; 9 (8) . https://dx.doi.org/10.2174/156802609789044443
DOI https://dx.doi.org/10.2174/156802609789044443 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interleukin-6 and Lung Inflammation: Evidence for a Causative Role in Inducing Respiratory System Resistance Increments
Inflammation & Allergy - Drug Targets (Discontinued) Inflammation, Oxidative Stress and Metabolic Syndrome: Dietary Modulation
Current Vascular Pharmacology Heme Oxygenase-1 in Lung Disease
Current Drug Targets Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) Cytokines in Human Breast Milk: Immunological Significance for Newborns
Current Nutrition & Food Science Role of Fibroblast Growth Factor 21 (FGF21) in the Regulation of Statural Growth
Current Pediatric Reviews Drug Delivery Systems for the Treatment of Diabetes Mellitus: State of the Art
Current Pharmaceutical Design Analysis of TLC-Bioautography and TLC-Spot Visualization of <i>Atropa accuminata</i> and <i>Atropa belladonna</i> Extracts as Antioxidant and Antibacterial Agents Against Human Pathogenic Bacteria
Current Pharmaceutical Analysis The Role of Lymphotoxin Receptor Signaling in Diseases
Current Molecular Medicine COVID-19-associated Coagulopathy and Thromboembolism: Determination of Their Patterns and Risk Factors as Predictors of Mortality Among Severe COVID-19 Patients
Current Vascular Pharmacology Functionally Engineered Nanosized Particles in Pharmaceutics: Improved Oral Delivery of Poorly Water-soluble Drugs
Current Pharmaceutical Design High Performance Liquid Chromatographic Approaches to Mass Spectrometry Based Metabolomics
Current Metabolomics Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Direct Selection of cDNAs from Filamentous Phage Surface Display Libraries: Potential and Limitations
Current Pharmaceutical Biotechnology Phosphoinositide 3-Kinases and Leukocyte Migration
Current Immunology Reviews (Discontinued) Serum Albumin Complexation of Acetylsalicylic Acid Metabolites
Current Drug Metabolism Anti-Inflammatory Drug Targeting in Asthma. Should Inhaled Corticosteroids Reach the Small Airways?
Current Drug Therapy Low Rank Representation and Its Application in Bioinformatics
Current Bioinformatics Lipid Rafts and Fas/CD95 Signaling in Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Editorial [Hot Topic: Molecular Targets in Chronic Obstructive Airway Diseases (Guest Editors: David A. Groneberg and Tobias Welte)]
Current Drug Targets